Exchange Traded Funds (ETFs) are a relatively new financial product that has experienced significant growth in the last few years. Leveraged, inverse, and inverse leveraged ETFs—new ETF structures that have become available over the last several years—have recently become the target of regulatory investigations and litigation. This article provides an introduction to ETFs in the context of recent regulatory problems and litigation.
Anticompetitive conduct and patents listed in the Orange Book
Branded pharmaceutical manufacturers are required by law to list all patents in the Orange Book that cover an approved drug product. However,...